Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 472 results found since Jan 2013.
Relevance of the diagnosis of hypersensitivity reactions to antineoplastic and biological agents: experience with drug provocation test
Conclusions. DPT followed by RSA allowed to exclude HSRs in 45 patients (55 culprit drugs). DPT before desensitization prevents non-hypersensitivity patients from undergoing RDD. In our study DPT was safe, all reactions were managed by an allergist.PMID:37133313 | DOI:10.23822/EurAnnACI.1764-1489.296
Source: European Annals of Allergy and Clinical Immunology - May 3, 2023 Category: Allergy & Immunology Authors: J Queir ós Gomes L P Pereira Dias P Barreira J Barradas Lopes M J Sousa S Cadinha D Malheiro Source Type: research
Molecular epidemiology and antifungal susceptibilities of Aspergillus species isolated from patients with invasive aspergillosis
CONCLUSION: Accurate identification of strains and antifungal susceptibility studies should be performed due to azole and amphotericin B resistance. Genotyping studies are important in infection control due to identifying sources of infection and transmission routes.PMID:36820712 | PMC:PMC9937602 | DOI:10.1590/1806-9282.20220441
Source: Cancer Control - February 23, 2023 Category: Cancer & Oncology Authors: Fatma Mutlu Sarig üzel Ayse Nedret Ko ç P ınar Sağiroğlu Mustafa Altay Atalay Arda Borlu Özlem Canöz Bedia Din ç Source Type: research
Drug allergy biomarkers
Although the true burden of drug allergy is unknown, several studies indicate that adverse drug reactions occur in up to 6% to 10% of hospitalized patients —20% of which are because of drug allergy—and up to 10% of the general population claims to have penicillin or other drug allergies.1 A plethora of new antibiotics, vaccines, chemotherapy drugs, and, more recently, biologicals and targeted molecular drugs are available and have improved disease treatment options, but drug allergy remains a vexing and unaddressed problem that deprives patients of the best medication for their disease, and when re-exposed, places them...
Source: Annals of Allergy, Asthma and Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Mariana Castells Tags: Editorial Source Type: research
Access To Outpatient Chemotherapy Desensitization Improved With Implementation Of A Multidisciplinary Pharmacy, Nursing, And Allergist Team
Desensitization allows preferred chemotherapy to be continued safely following initial hypersensitivity reactions (iHSRs). However, desensitization is resource-intensive, often requiring Intensive Care Unit (ICU) stays and meticulous care coordination with nursing and pharmacy. A multidisciplinary team-based approach could enable outpatient desensitization while minimizing healthcare burden and costs.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Rose Monahan, Fernanda Young, Emely Alfaro, Carlo Legasto, Dorothy Wang, Jessica Zheng, Lulu Tsao, Hansen Ho, Iris Otani Source Type: research
Outcomes of Single Bag Protocols for Desensitization to Antineoplastic Agents
The typical drug desensitization process includes three separate intravenous infusions with each bag containing an increasing concentration of the drug. Many biologics and chemotherapy agents may not be diluted past a specific concentration or diluted protocols are prohibitively long, making a single bag desensitization protocol useful. The aim of this case series is to describe the safety and efficacy of single bag desensitization protocols in two oncology patients.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Erika Raley, Mahboobeh Mahdavinia Source Type: research
Assessing our Chemotherapy and Biologics Drug Desensitization Center
The recent validation of delabeling tools and new desensitization protocols for patients with hypersensitivity to chemotherapy and biologics(ChB) has refined the diagnostic and
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Paula Vazquez Revuelta, Ricardo Madrigal-Burgaleta, Gustavo Molina Molina, Kevin Molina Mata, Carmen Mu ñoz Serrano, Ramon Lleonart Bellfill Source Type: research
Multiple Reactions and Increased Infusion Time During Desensitization May Decrease the Efficacy of Pegaspargase Chemotherapy
Asparaginase therapy improves survival in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma and is considered a critical component of chemotherapy. However, 10-25% of patients experience immediate hypersensitivity reactions to the preferred asparaginase chemotherapeutic agent, pegaspargase. In the setting of limited supply of the main alternative agent, Erwinia asparaginase, patients may not be able to receive asparaginase therapy unless they undergo desensitization. While cases of successful desensitizations to pegaspargase have been described, our center ’s experience has demonstrated challenges in effectively de...
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Elizabeth Gilje, Christine Cho, Laura Ann Wang Source Type: research
Analysis of risk factors related to acute radiation dermatitis in breast cancer patients during radiotherapy
Conclusions: ARD in response to postoperative radiotherapy in patients with breast cancer is common and mild. Clinicians and patients need to cultivate awareness of the potential risk factors involved and then intervene to alleviate skin reactions and improve the quality of life.
Source: Journal of Cancer Research and Therapeutics - January 11, 2023 Category: Cancer & Oncology Authors: Di Liu Zhewen Zheng Shuyuan Zhang Chunmei Zhu Hongyan Zhang Yunfeng Zhou Source Type: research
